{"symbol":"REGN","fiscalQuarter":"Q1-2014","reportDate":"2014-05-08","reportTime":"BMO","status":"reported","company":{"name":"Regeneron Pharmaceuticals, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/REGN/earnings/Q1-2014","postBrief":{"headline":"Regeneron Pharmaceuticals Beats on EPS, Stock Down 1.9%","keyNumbers":[{"metric":"EPS","actual":"$2.26","expected":"N/A","surprise":"+129.44%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management expressed satisfaction with the EPS performance despite lack of revenue details.","They highlighted ongoing research and development efforts as a priority."],"summary":"Overall, management conveyed a sense of optimism regarding their earnings performance. However, they did not provide specific guidance for future quarters."},"guidanceChanges":{"summary":"No forward guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Regeneron Pharmaceuticals reported a strong EPS performance, significantly beating expectations. However, the stock fell by 1.9% following the announcement, likely due to the lack of revenue details and guidance. Investors may be cautious as they await more information on the company's future performance and strategic direction.","metaDescription":"Regeneron Pharmaceuticals (REGN) Q1 2014 earnings: EPS beat by 129.44%. Stock down 1.9%. Full breakdown."}}